{"public_id":"cl_2cc2e0614b45ed5cdb450e70d32af29d","status":"active","superseded_by_public_id":null,"corpus_id":1215691,"text":"Rituximab is increasingly regarded as an established therapy with long-term efficacy and an acceptable safety profile in neuromyelitis optica patients.","confidence":0.93,"paper":{"corpus_id":1215691,"title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)","url":"https://sah.borca.ai/papers/1215691"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_049fba9ee226520639ab8056aec17be9","name":"safety profile","description":"The pattern and acceptability of adverse effects associated with a treatment.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_049fba9ee226520639ab8056aec17be9"},{"public_id":"co_261600116dddd708f9f49aaf068661ab","name":"rituximab","description":"A monoclonal antibody used as an immunotherapy for neuromyelitis optica.","types":["drug","biological therapy"],"url":"https://sah.borca.ai/concepts/co_261600116dddd708f9f49aaf068661ab"},{"public_id":"co_36956381dd0686ef36a296c306e186f6","name":"long-term efficacy","description":"Sustained treatment benefit over an extended follow-up period.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_36956381dd0686ef36a296c306e186f6"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_2cc2e0614b45ed5cdb450e70d32af29d"}